Mon Sep 09 15:12:00 UTC 2024: ## Scinai Immunotherapeutics Leverages Alpaca Antibodies for Innovative Treatments: BioMedWire Podcast Features CEO Amir Reichman

**LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) –** InvestorBrandNetwork (IBN), a leading communications organization connecting public companies with investors, released a new episode of its popular BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics is a biopharmaceutical company dedicated to developing novel biological products for inflammation and immunology, while also offering CDMO services through its Scinai Bioservices division. Reichman highlighted the company’s unique approach, utilizing VHH single domain antibodies derived from alpacas. These antibodies, licensed from Germany’s Max Planck Institute and the University Medical Centre Göttingen, hold significant promise for developing innovative therapies.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” said Reichman. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Reichman emphasized the importance of collaborating with world-class researchers, noting, “Many people say that it’s more important to know who your supervisors and mentors were for your PhD than to know the research topic of your PhD… It sounds like a cliché, but it’s really important to find and collaborate with the best minds. In my experience, the probability that inventions (from such world class researcher) will then materialize into actual commercial products that are safe and efficacious is significantly higher.”

Scinai’s strategy centers on de-risking by focusing on molecular targets already explored by other manufacturers. The company identifies patient populations who are currently undertreated and leverages the unique properties of alpaca antibodies to develop “bio-better” treatments.

The BioMedWire Podcast episode with Amir Reichman delves deeper into Scinai’s recent milestones, providing valuable insights into the company’s innovative approach to tackling unmet medical needs. You can access the episode and subscribe for future podcasts at https://podcast.biomedwire.com.

Read More